Welcome to our dedicated page for Bausch Health Companies news (Ticker: BHC), a resource for investors and traders seeking the latest updates and insights on Bausch Health Companies stock.
Bausch Health Companies Inc. reports news on its global diversified pharmaceutical business, including financial results, guidance, debt refinancing activity and updates from its operating businesses. The company develops, manufactures and markets products in gastroenterology, hepatology, neuroscience, dermatology, dentistry, aesthetics, international pharmaceuticals and eye health through its controlling interest in Bausch + Lomb.
Recurring company updates include Salix gastroenterology programs, Ortho Dermatologics skincare and patient-support initiatives, Solta Medical aesthetic device launches, and quarterly performance for Bausch Health excluding Bausch + Lomb. News also covers product availability, regulatory clearances for medical aesthetic devices, clinical-program disclosures and capital-structure actions.
Bausch Health Companies (NYSE/TSX:BHC) announced a favorable ruling from the US District Court for the District of New Jersey regarding its products DUOBRII and BRYHALI. The court upheld the validity of all asserted patents, preventing the approval of generics by Padagis Israel Pharmaceuticals until the patents expire in 2031 and 2036, respectively. This decision reinforces Bausch Health's commitment to its patent portfolio and the strength of its intellectual property. DUOBRII and BRYHALI are both topical medications for treating plaque psoriasis.
Salix Pharmaceuticals, part of Bausch Health (NYSE:BHC), has launched new social media initiatives for Constipation Awareness Month in December. This campaign raises awareness about constipation-related diseases including opioid-induced constipation, irritable bowel syndrome with constipation, and chronic idiopathic constipation. Salix's efforts include collaborations with influencers and extensive educational content that reached over 240 million consumers in 2022. The company aims to enhance public understanding of gastrointestinal disorders and will continue working with patient advocacy groups to support education and research in 2023.
Bausch Health Companies Inc. (NYSE:BHC) has declared 1261229 B.C. Ltd. as an unrestricted subsidiary, which controls 88.7% of Bausch + Lomb Corporation. This change means Bausch + Lomb and its subsidiaries are no longer bound by Bausch Health's debt covenants. The company is actively exploring options to optimize stakeholder value, focusing on balance sheet and liquidity strategies. These developments may impact the company's financial flexibility and strategic positioning moving forward.
KBRA has published its third-quarter 2022 U.S. Bank Compendium and 2023 Sector Outlook, analyzing results for U.S. banks. The report acknowledges the resilience of rated banks amid tightening economic conditions, citing improved capital profiles and higher loss buffers. Despite economic uncertainties, the report maintains a Stable Outlook for the U.S. banking industry. Key metrics, trends, and the top performing banks based on deposit costs and reserves are discussed. The Compendium also includes a quarterly ESG Bulletin featuring Berkshire Hills Bancorp, Inc. (BHLB).
Bausch Health Companies Inc. (NYSE:BHC) announced the presentation of a de novo abstract at The Liver Meeting® 2022 in Washington, D.C., from November 4-8. The abstract is titled "Rifaximin Plus Lactulose Versus Lactulose Alone for Reducing the Risk of Overt Hepatic Encephalopathy Recurrence: A Pooled Subgroup Analysis." XIFAXAN® (rifaximin) is indicated for the reduction of overt hepatic encephalopathy recurrence and treatment of irritable bowel syndrome with diarrhea. The company emphasizes safety information related to XIFAXAN use.
Bausch Health Companies reported third-quarter 2022 revenues of $2.046 billion, marking a 3% decline year-over-year, attributed to foreign exchange and divestitures. Despite this, organic revenue grew by 2%. The company also executed a successful debt exchange, reducing debt by $2.5 billion, which is expected to enhance financial flexibility. Operating income decreased significantly to $244 million from $574 million in Q3 2021 due to rising expenses and lower revenues. Bausch Health updated its full-year guidance, projecting revenues between $8.0 - $8.17 billion.
Bausch Health Companies (NYSE:BHC) and its dermatology division, Ortho Dermatologics, announced the presentation of nine posters at the Innovations in Dermatology Conference on Nov. 3-5, 2022, in Las Vegas. The posters will highlight new analyses of JUBLIA (efinaconazole) and SILIQ (brodalumab), along with encore presentations of DUOBRII and ARAZLO. Ortho Dermatologics aims to engage with dermatologists and provide insights on their products, including the recently recognized JUBLIA, which received the APMA Seal of Approval.
Bausch Health Companies Inc. (NYSE:BHC) has launched the Podiatry Board Review Challenge, a professional educational resource aimed at supporting podiatry residents and professionals with board certification and re-certification exams. Developed with input from practicing podiatrists, the Challenge offers 200 free questions across various medical topics. Additionally, 300 new questions have been added to the existing Dermatology Board Review Challenge. Bausch Health aims to enhance education in the podiatry field, thereby improving patient care.
Bausch Health Companies Inc. (NYSE:BHC) and its gastroenterology division, Salix Pharmaceuticals, presented significant findings on XIFAXAN (rifaximin), TRULANCE (plecanatide), and RELISTOR (methylnaltrexone bromide) at the ACG 2022 Annual Scientific Meeting (October 21-26, Charlotte, NC). The studies showcased advancements in treating irritable bowel syndrome (IBS) and opioid-induced constipation (OIC), indicating improved patient outcomes. The research highlights the effectiveness of these medications in managing associated symptoms, potentially enhancing market confidence in BHC's gastroenterology portfolio.
Bausch Health Companies (NYSE:BHC) announced the presentation of eleven posters at the Fall Clinical Dermatology Conference from October 20-23, 2022, in Las Vegas. The posters will cover new analyses related to ARAZLO (tazarotene) Lotion, DUOBRII (halobetasol propionate and tazarotene) Lotion, and the investigational IDP-126 Gel. Additionally, the presentation includes adaptations on SILIQ (brodalumab) Injection and five encore presentations, showcasing advancements in dermatological treatments. This reflects the company’s commitment to research and patient safety.